Life-changing medication for leukaemia and lymphoma patients will soon be within reach for more than 900 Australians.
Prime Minister Malcolm Turnbull will announce on Monday that Ibrutinib – known as Imbruvica – will be listed on the pharmaceutical benefits scheme from December at a cost of $466 million.
The medicine which normally costs $187,390 per course of treatment will be reduced to $38.80 per script or $6.30 for concessional patients.
It will be available to eligible patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.
Normally Ibrutinib is used when patients have not responded to first line treatment with chemo-immuno-therapy.Do you have an idea for a story?
Email [email protected]